Invesco’s Y-mAbs Therapeutics YMAB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-42,833
| Closed | -$193K | – | 3867 |
|
|
2025
Q2 | $193K | Buy |
42,833
+10,286
| +32% | +$46.2K | ﹤0.01% | 3517 |
|
|
2025
Q1 | $144K | Buy |
32,547
+17,624
| +118% | +$102K | ﹤0.01% | 3580 |
|
|
2024
Q4 | $117K | Buy |
14,923
+367
| +3% | +$4.47K | ﹤0.01% | 3605 |
|
|
2024
Q3 | $191K | Buy |
14,556
+329
| +2% | +$4.17K | ﹤0.01% | 3527 |
|
|
2024
Q2 | $172K | Buy |
14,227
+939
| +7% | +$12.7K | ﹤0.01% | 3662 |
|
|
2024
Q1 | $216K | Buy |
13,288
+27
| +0.2% | +$364 | ﹤0.01% | 3616 |
|
|
2023
Q4 | $90.4K | Buy |
13,261
+1,477
| +13% | +$8.54K | ﹤0.01% | 3698 |
|
|
2023
Q3 | $64.2K | Hold |
11,784
| – | – | ﹤0.01% | 3776 |
|
|
2023
Q2 | $80K | Sell |
11,784
-1,746
| -13% | -$13.1K | ﹤0.01% | 3763 |
|
|
2023
Q1 | $67.8K | Sell |
13,530
-819
| -6% | -$3.34K | ﹤0.01% | 3739 |
|
|
2022
Q4 | $70K | Sell |
14,349
-2,454
| -15% | -$17.8K | ﹤0.01% | 3880 |
|
|
2022
Q3 | $242K | Sell |
16,803
-98,499
| -85% | -$1.63M | ﹤0.01% | 3614 |
|
|
2022
Q2 | $1.75M | Buy |
115,302
+100,158
| +661% | +$1.17M | ﹤0.01% | 2764 |
|
|
2022
Q1 | $180K | Buy |
15,144
+111
| +0.7% | +$1.14K | ﹤0.01% | 3791 |
|
|
2021
Q4 | $244K | Sell |
15,033
-1,396
| -8% | -$29.8K | ﹤0.01% | 3706 |
|
|
2021
Q3 | $469K | Buy |
16,429
+2,563
| +18% | +$80.8K | ﹤0.01% | 3456 |
|
|
2021
Q2 | $468K | Buy |
13,866
+5,363
| +63% | +$172K | ﹤0.01% | 3448 |
|
|
2021
Q1 | $257K | Buy |
8,503
+2,169
| +34% | +$88.9K | ﹤0.01% | 3601 |
|
|
2020
Q4 | $314K | Buy |
+6,334
| New | +$293K | ﹤0.01% | 3400 |
|
|
2020
Q3 | – | Sell |
-85,061
| Closed | -$3.67M | – | 3695 |
|
|
2020
Q2 | $3.67M | Buy |
+85,061
| New | +$3.22M | ﹤0.01% | 2163 |
|
Other funds holding YMAB
Invesco's YMAB Position: Q3 2025 in Review
Invesco sold out of Y-mAbs Therapeutics (YMAB) in Q3 2025, closing a stake of 42,833 shares — an estimated $193K sold.
Invesco first reported a position in YMAB in Q2 2020 and held it in 20 quarters. The position peaked at $3.67M in Q2 2020. 2 funds tracked by Wall St. Rank hold YMAB as of Q3 2025.
- Invesco reported no remaining Y-mAbs Therapeutics position as of Q3 2025 after selling out during the quarter.
- Invesco sold 42,833 Y-mAbs Therapeutics shares in Q3 2025, an estimated $193K.
- Invesco first reported a position in Y-mAbs Therapeutics in Q2 2020 and held it in 20 quarters.
- Invesco's Y-mAbs Therapeutics position peaked at $3.67M in Q2 2020.
- 2 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q3 2025.
Based on Invesco's 13F filing for Q3 2025, filed 13 Nov 2025.